» Articles » PMID: 31668022

Tracking Muscle Wasting and Disease Activity in Facioscapulohumeral Muscular Dystrophy by Qualitative Longitudinal Imaging

Overview
Date 2019 Nov 1
PMID 31668022
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Facioscapulohumeral muscular dystrophy (FSHD) is one of the most frequent late-onset muscular dystrophies, characterized by progressive fatty replacement and degeneration involving single muscles in an asynchronous manner. With clinical trials at the horizon in this disease, the knowledge of its natural history is of paramount importance to understand the impact of new therapies. The aim of this study was to assess disease progression in FSHD using qualitative muscle magnetic resonance imaging, with a focus on the evolution of hyperintense lesions identified on short-tau inversion recovery (STIR+) sequences, hypothesized to be markers of active muscle injury.

Methods: One hundred genetically confirmed consecutive FSHD patients underwent lower limb muscle magnetic resonance imaging at baseline and after 365 ± 60 days in this prospective longitudinal study. T1 weighted (T1w) and STIR sequences were used to assess fatty replacement using a semiquantitative visual score and muscle oedema. The baseline and follow-up scans of each patient were also evaluated by unblinded direct comparison to detect the changes not captured by the scoring system.

Results: Forty-nine patients showed progression on T1w sequences after 1 year, and 30 patients showed at least one new STIR+ lesion. Increased fat deposition at follow-up was observed in 13.9% STIR+ and in only 0.21% STIR- muscles at baseline (P < 0.001). Overall, 89.9% of the muscles that showed increased fatty replacement were STIR+ at baseline and 7.8% were STIR+ at 12 months. A higher number of STIR+ muscles at baseline was associated with radiological worsening (odds ratio 1.17, 95% confidence interval 1.06-1.30, P = 0.003).

Conclusions: Our study confirms that STIR+ lesions represent prognostic biomarkers in FSHD and contributes to delineate its radiological natural history, providing useful information for clinical trial design. Given the peculiar muscle-by-muscle involvement in FSHD, MRI represents an invaluable tool to explore the modalities and rate of disease progression.

Citing Articles

Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study.

Fionda L, Leonardi L, Tufano L, Lauletta A, Morino S, Merlonghi G J Neurol. 2024; 271(9):5864-5874.

PMID: 38972019 PMC: 11377679. DOI: 10.1007/s00415-024-12544-5.


AI driven analysis of MRI to measure health and disease progression in FSHD.

Riem L, DuCharme O, Cousins M, Feng X, Kenney A, Morris J Sci Rep. 2024; 14(1):15462.

PMID: 38965267 PMC: 11224366. DOI: 10.1038/s41598-024-65802-x.


French National Protocol for diagnosis and care of facioscapulohumeral muscular dystrophy (FSHD).

Attarian S, Beloribi-Djefaflia S, Bernard R, Nguyen K, Cances C, Gavazza C J Neurol. 2024; 271(9):5778-5803.

PMID: 38955828 DOI: 10.1007/s00415-024-12538-3.


A deep learning approach for fast muscle water T2 mapping with subject specific fat T2 calibration from multi-spin-echo acquisitions.

Barbieri M, Hooijmans M, Moulin K, Cork T, Ennis D, Gold G Sci Rep. 2024; 14(1):8253.

PMID: 38589478 PMC: 11002020. DOI: 10.1038/s41598-024-58812-2.


Muscle fibrosis as a prognostic biomarker in facioscapulohumeral muscular dystrophy: a retrospective cohort study.

Ragozzino E, Bortolani S, Di Pietro L, Papait A, Parolini O, Monforte M Acta Neuropathol Commun. 2023; 11(1):165.

PMID: 37849014 PMC: 10583430. DOI: 10.1186/s40478-023-01660-4.


References
1.
Jagannathan S, Shadle S, Resnick R, Snider L, Tawil R, van der Maarel S . Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells. Hum Mol Genet. 2017; 25(20):4419-4431. PMC: 6078597. DOI: 10.1093/hmg/ddw271. View

2.
Lim J, Snider L, Yao Z, Tawil R, van der Maarel S, Rigo F . DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD. Hum Mol Genet. 2015; 24(17):4817-28. PMC: 4527486. DOI: 10.1093/hmg/ddv206. View

3.
Ferguson M, Poliachik S, Budech C, Gove N, Carter G, Wang L . MRI change metrics of facioscapulohumeral muscular dystrophy: Stir and T1. Muscle Nerve. 2017; 57(6):905-912. DOI: 10.1002/mus.26038. View

4.
Teveroni E, Pellegrino M, Sacconi S, Calandra P, Cascino I, Farioli-Vecchioli S . Estrogens enhance myoblast differentiation in facioscapulohumeral muscular dystrophy by antagonizing DUX4 activity. J Clin Invest. 2017; 127(4):1531-1545. PMC: 5373881. DOI: 10.1172/JCI89401. View

5.
Tasca G, Monforte M, Corbi M, Granata G, Lucchetti D, Sgambato A . Muscle Microdialysis to Investigate Inflammatory Biomarkers in Facioscapulohumeral Muscular Dystrophy. Mol Neurobiol. 2017; 55(4):2959-2966. DOI: 10.1007/s12035-017-0563-x. View